Navigation Links
Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Date:9/11/2007

- Additional Phase 3 Trials on Track for Initiation Later This Year -

- Conference Call Scheduled for Today at 8:30 a.m. Eastern Time -

SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that an independent Echocardiographic Data Safety Monitoring Board (the Board or EDSMB) found no reason to stop the ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management). The BLOOM trial is evaluating the efficacy and safety of lorcaserin hydrochloride for the treatment of obesity. The findings of the Board were based on a planned detailed review of unblinded echocardiograms performed after patients completed six months of dosing in the trial. The review was conducted by the Board and confirms that differences, if any, in the rates of U.S. Food and Drug Administration (FDA)-defined valvulopathy in patients treated with lorcaserin and in the control group did not meet predetermined stopping criteria. The review also confirmed that the rate of FDA-defined valvulopathy in the placebo group is consistent with the company's statistical powering assumptions used in the design of the pivotal trial program to monitor patients for any increased risk of developing valvulopathy. Arena is currently in discussions with the FDA to finalize protocols for two additional Phase 3 pivotal trials scheduled to begin later this year.

"Patient safety is and always has been a primary focus for Arena in our effort to fully explore and understand lorcaserin's profile and its potential to safely help a significant number of patients that are obese or overweight improve their health by better managing their weight," said Jack Lie
'/>"/>

SOURCE Arena Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Traveling stem cell show continues state tour
4. AT&T - BellSouth merger: Revestiture continues
5. Madison biotech continues its climb
6. Brady continues growth through Asian acquisition
7. Transition continues to impact Third Wave financials
8. Line between big pharma, big biotech continues to blur
9. Wisconsin giant continues to dominate the health care IT market
10. API Software continues expansion
11. Third Wave continues molecular diagnostic focus with new CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today ... Inc., to provide access to Nanosyn,s microfluidics screening ... platform for novel small molecule therapeutics. ... to work with FORMA Therapeutics to explore key ... homeostasis. FORMA Therapeutics, decision to work with us ...
(Date:7/29/2014)... TransVac Solutions, the trusted leader in automated ... for hospitals, will be exhibiting at booth #209 at ... & Technical Exhibition Aug. 3-6 in Chicago, Ill. ... hospitals cleaner, reducing infection risk and saving millions in ... Staff will be available at booth #209 to ...
(Date:7/29/2014)... , July 29, 2014  Sigma-Aldrich Corporation (NASDAQ: ... and energy use, increased its investment in Green Chemistry ... around the world last year, the Company announced Monday ... if Science Changed the World? The ... several honors for being a responsible corporate citizen, including ...
(Date:7/29/2014)... G-CON Manufacturing Inc., the standard in design and ... leadership appointment designed to drive the company’s ambitious growth ... Maik Jornitz, Chief Operating Officer of G-Con Manufacturing, has ... the pioneering company through its next phase of market ... and look forward to providing our next generation of ...
Breaking Biology Technology:Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2
... Madison, Wis. - Sometimes the small things do count. ... recently received $300,000 in initial investor funding. The Middleton, ... million through equity financing and a National Science ... cloning technology that has been deemed revolutionary by some. ...
... Friday that its flagship product Mediasite Live ... 2003 Award . The Madison-based company provides media communications ... NEC Electronics and Sony Pictures Digital . The ... Creston , and Extron Electronics to provide ...
... morning, I asked the question I hoped never to ask the ... moment I thought I had a reprieve, a good excuse. "I'm ... , ,After a beat, she added with a smile, "But ... ,Fantastic, I thought at first, not realizing completely the repercussions of ...
Cached Biology Technology:Lucigen Receives Funding, Breaks New Ground with Enzyme Research 2Technology with Aloha 2Technology with Aloha 3Technology with Aloha 4
(Date:7/28/2014)... John Essigmann and colleagues from the University of Washington had ... they could induce the virus to mutate uncontrollably, they could ... strategy that our immune system uses against many viruses. ... to mutate at an enhanced rate, as expected. But it ... clinical trial reported in 2011. In a new study, however, ...
(Date:7/28/2014)... the top 10 U.S. cities that have seen an ... as frequent road closures, overwhelmed storm drains and compromised ... NOAA technical report. , This nuisance flooding, caused by ... coasts, between 300 and 925 percent since the 1960s. ... Frequency Changes around the United States, also finds Annapolis ...
(Date:7/28/2014)... himself the bug hunter, but the target of his ... and identified with special methods and instruments. Benjamin Hause, ... Diagnostic Laboratory at Kansas State University, recently published an ... which is an important find in the United States. ... didn,t know what it was," Hause said. "We used ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... researchers, with the help of a groundbreaking medical device, ... will provide relief for the hundreds of thousands of ... with epilepsy or other neurologic disorders. The impact ... lack of societal contribution is immeasurable, said Gretchen Birbeck, ...
... field of "personalized" or "precision" medicine holds great promise ... the genetic changes that drive each patient,s cancer cells, ... But achieving this goal will require massive amounts of ... manage and analyze the data. The University of ...
... of the America Invents Act into law led to the ... years. These reforms will have a significant impact on technology ... in Industrial Biotechnology , a peer-reviewed journal from ... online on the Industrial Biotechnology website. ...
Cached Biology News:Drug could reverse scourge of cerebral malaria for survivors 2Drug could reverse scourge of cerebral malaria for survivors 3UC Santa Cruz builds national data center for cancer genome research 2UC Santa Cruz builds national data center for cancer genome research 3UC Santa Cruz builds national data center for cancer genome research 4UC Santa Cruz builds national data center for cancer genome research 5How will the US biotechnology industry benefit from new patent laws? 2
...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... Although the mixed TAMRA isomers are ... isomers are increasingly preferred for labeling peptides ... in HPLC purification that is often required ... often used than 6-TAMRA for labeling peptides ...
Biology Products: